BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–
small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF …

Diaper dermatitis is the most common contact eczema present in early childhood. The main
cause is an irritant reaction to urine and feces, which is facilitated by the occlusive conditions …

Langerhans cell histiocytosis (LCH) is characterized by granulomatous lesions with
pathologic CD2071 dendritic cells. 1 More than 40% of children with high-risk LCH …

Langerhans cell histiocytosis (LCH) is a disorder of myeloid neoplasia of dendritic cells that
affects 1 in 200,000 children< 15 years of age and even fewer adults. LCH presents with a …

Histiocytic disorders are rare diseases defined by the clonal accumulation of a macrophage
or dendritic cell origin. These disorders include Langerhans cell histiocytosis, Erdheim …

Erdheim–Chester disease (ECD) is a rare clonal histiocytic neoplasm with less than 1200
documented cases to date. The disease is life-threatening and difficult to recognize …

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare smoking-related lung disease
characterized by dendritic cell (DC) accumulation, bronchiolocentric nodule formation, and …

Mitogen-activating protein kinase pathway alterations in Lan... : Current Opinion in Oncology
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis : Current …

Almost half of the patients with Langerhans cell histiocytosis (LCH) are refractory to primary
induction chemotherapy or undergo reactivation. The ideal treatment modality for …

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group”
histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are …